Rafael Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Rafael Holdings, Inc. on November 15, 2018. The company is incorporated in Delaware and operates with principal executive offices in Newark, New Jersey. The report details a specific financing event occurring on the date of the report.
Key Financial Metrics
The filing discloses a new debt instrument rather than periodic financial performance metrics such as revenue or operating margins.
- Convertible Note Principal: $15 million
- Interest Rate: 6% per annum, compounded quarterly
- Note Term: Three years
- Conversion Price: $8.47 per share (Class B common stock)
- Initial Conversion Shares: 1,770,956 shares
- Maximum Conversion Shares (with capitalized interest): 2,117,388 shares
Material Changes
The primary material change is the execution of an agreement on November 15, 2018, wherein Howard Jonas purchased a $15 million convertible note from the Company. This transaction introduces new debt obligations and potential equity dilution depending on future conversion events.
Outlook, Management Commentary, and Risks
Use of Proceeds: Management intends to use the funds to exercise additional portions of its warrant to purchase equity of Rafael Pharmaceuticals, Inc., for general corporate needs, and to retain flexibility for opportunities in its real estate business.
Terms and Contingencies:
- Interest may be paid in cash or capitalized at the Company's option.
- The note is convertible at the holder's option.
- The Company holds a forced conversion right if the Class B common stock price reaches 200% of the conversion price ($16.94) for at least 30 consecutive days.
Risks: The filing does not explicitly list new risks beyond the standard implications of convertible debt, such as potential dilution of existing shareholders upon conversion.
Investor Verification Checklist
- Verify the current trading price of Class B common stock relative to the $8.47 conversion price and the $16.94 forced conversion threshold.
- Confirm the status of the warrant to purchase equity in Rafael Pharmaceuticals, Inc., to assess the likelihood of the stated use of proceeds.
- Review the Company's cash flow position to determine if interest will be paid in cash or capitalized.
- Check for any subsequent filings regarding the actual exercise of the warrant or conversion of the note.